• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    5 Cheapest Health Care Stocks You Should Think About

    1/13/23 8:45:37 AM ET
    $BAX
    $CUTR
    $TCDA
    $VERA
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BAX alert in real time by email

    The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

    The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30.

    Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

    Tricida, Inc. (NASDAQ:TCDA)

    • The company’s stock dropped around 98% over the past six months. The company’s stock has a 52-week low of $0.13 .
    • RSI Value: 28.21
    • TCDA Price Action: Shares of Tricida fell 9.1% to settle at $0.1681 on Thursday and added 1.7% in today’s pre-market trading.


    Baxter International Inc. (NYSE:BAX)

    • Wells Fargo maintained Baxter Intl with an Equal-Weight and lowered the price target from $57 to $52. The company’s stock has a 52-week low of $44.47.
    • RSI Value: 29.64
    • BAX Price Action: Shares of Baxter International fell 0.8% to close at $45.09 on Thursday and lost 9.7% in today’s pre-market trading.


    Vera Therapeutics, Inc. (NASDAQ:VERA)

    • Vera Therapeutics announced topline results of the Phase 2b ORIGIN clinical trial of atacicept for the treatment of IgA nephropathy. The company’s stock has a 52-week low of $5.20.
    • RSI Value: 20.51
    • VERA Price Action: Shares of Vera Therapeutics rose 1.9% to close at $6.02 on Thursday and lost 0.8% in today’s pre-market trading.


    Third Harmonic Bio, Inc. (NASDAQ:THRD)

    • Morgan Stanley, last month, downgraded Third Harmonic Bio from Overweight to Equal-Weight and lowered the price target from $34 to $5. The company’s 52-week low is $3.89.
    • RSI Value: 24.97
    • THRD Price Action: Shares of Third Harmonic Bio gained 3.5% to close at $4.49 on Thursday and added 1.6% in after-hours trading.


    Cutera, Inc. (NASDAQ:CUTR)

    • Maxim Group maintained Cutera with a Buy and lowered the price target from $80 to $55. The company has a 52-week low of $26.51.
    • RSI Value: 20.03
    • CUTR Price Action: Shares of Cutera rose 3.8% to close at $28.84 on Thursday and added 2.6% in pre-market trading.

    Read More: Fear & Greed Index Moves To 'Greed' Zone Following Inflation Report

    Get the next $BAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAX
    $CUTR
    $TCDA
    $VERA

    CompanyDatePrice TargetRatingAnalyst
    Baxter International Inc.
    $BAX
    10/31/2025Buy → Hold
    Argus
    Vera Therapeutics Inc.
    $VERA
    10/16/2025$48.00Buy
    BofA Securities
    Vera Therapeutics Inc.
    $VERA
    8/4/2025Outperform → Peer Perform
    Wolfe Research
    Baxter International Inc.
    $BAX
    8/4/2025$25.00Buy → Hold
    Stifel
    Baxter International Inc.
    $BAX
    8/1/2025$25.00Buy → Neutral
    Goldman
    Vera Therapeutics Inc.
    $VERA
    5/5/2025$75.00Buy
    H.C. Wainwright
    Baxter International Inc.
    $BAX
    2/26/2025$42.00Buy
    Goldman
    Baxter International Inc.
    $BAX
    2/24/2025Hold → Buy
    Argus
    More analyst ratings

    $BAX
    $CUTR
    $TCDA
    $VERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Baxter downgraded by Argus

    Argus downgraded Baxter from Buy to Hold

    10/31/25 8:47:22 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    BofA Securities initiated coverage on Vera Therapeutics with a new price target

    BofA Securities initiated coverage of Vera Therapeutics with a rating of Buy and set a new price target of $48.00

    10/16/25 8:29:17 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics downgraded by Wolfe Research

    Wolfe Research downgraded Vera Therapeutics from Outperform to Peer Perform

    8/4/25 8:19:45 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BAX
    $CUTR
    $TCDA
    $VERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcdonnell Michael R. was granted 1,811 shares (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    2/18/26 4:06:26 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    New insider Mcdonnell Michael R. claimed no ownership of stock in the company (SEC Form 3)

    3 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    2/18/26 4:04:14 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Group Pres., ITT & Pharma. Soriano Maria Cecilia was granted 2,273 shares and covered exercise/tax liability with 918 shares, increasing direct ownership by 2% to 56,006 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    2/11/26 7:11:08 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    $CUTR
    $TCDA
    $VERA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Enright Patrick G bought $249,985 worth of shares (5,882 units at $42.50) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    12/15/25 8:07:34 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Enright Patrick G bought $5,277,311 worth of shares (250,000 units at $21.11) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    6/25/25 8:07:16 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Katabi Maha bought $4,999,990 worth of shares (161,290 units at $31.00) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/1/24 5:58:54 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BAX
    $CUTR
    $TCDA
    $VERA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Vera Therapeutics Inc.

    SCHEDULE 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

    2/17/26 10:26:21 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Baxter International Inc.

    10-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    2/12/26 4:46:04 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Leadership Update, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    2/12/26 7:17:39 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    $CUTR
    $TCDA
    $VERA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baxter Reports Fourth-Quarter 2025 Results

    Fourth-quarter sales from continuing operations of $2.97 billion increased 8% on a reported basis and 3% on an operational basis1,2 Fourth-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($2.01); adjusted diluted EPS from continuing operations of $0.44 Company advances ongoing board of directors refreshment Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025. "While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations, underscoring the importance of our focus on driving continuous improvement across the enterprise," said And

    2/12/26 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 11,500 shares of Class A common stock and restricted stock units (RSUs) underlying 5,750 shares of Class A common stock to two (2) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stoc

    2/6/26 4:05:00 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

    BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. "We are pleased to welcome Matt to the executive team as we prepare for the potential commercial launch of atacicept for the treatment of IgA nephropathy," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "With his track record

    1/28/26 7:30:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BAX
    $CUTR
    $TCDA
    $VERA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    $CUTR
    $TCDA
    $VERA
    Leadership Updates

    Live Leadership Updates

    View All

    Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

    BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. "We are pleased to welcome Matt to the executive team as we prepare for the potential commercial launch of atacicept for the treatment of IgA nephropathy," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "With his track record

    1/28/26 7:30:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

    BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience to Vera Therapeutics' Board of Directors. "We are thrilled to welcome Jim to our Board of Directors at this pivotal point in Vera Therapeutics' history as we prepare to launch a potential first-in-class dual BAFF/APRIL inhibitor to transform the treatment of IgA nephropathy and other aut

    11/26/25 4:05:00 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Baxter Appoints Andrew Hider Chief Executive Officer

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    $BAX
    $CUTR
    $TCDA
    $VERA
    Financials

    Live finance-specific insights

    View All

    Baxter Reports Fourth-Quarter 2025 Results

    Fourth-quarter sales from continuing operations of $2.97 billion increased 8% on a reported basis and 3% on an operational basis1,2 Fourth-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($2.01); adjusted diluted EPS from continuing operations of $0.44 Company advances ongoing board of directors refreshment Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025. "While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations, underscoring the importance of our focus on driving continuous improvement across the enterprise," said And

    2/12/26 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter to Host Fourth-Quarter 2025 Financial Results Conference Call for Investors

    Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its fourth-quarter 2025 financial results on Thursday, February 12, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I81994118 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and eve

    1/21/26 5:00:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Announces Pricing of Tender Offers for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the consideration payable in connection with the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The table below sets forth the Total Consideration (as defined below) for each series of Notes. Title of Security CUSIP Number(1) Principal Amount Outstanding U.S. Treasury Reference Security Bloomberg Reference Page Reference Yield Fixed Spread Early Tender Payment (3)(4) Total Consideration(3)(4) 2.600% Senior Unsecured Notes due 2026 071813BQ1 $750,000,000 UST 1.500% due Aug. 15, 2026 FIT3 3.713% +30 bps $30

    12/4/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    $CUTR
    $TCDA
    $VERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

    SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

    11/14/24 4:10:28 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

    SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

    11/14/24 4:05:17 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Vera Therapeutics Inc.

    SC 13G - Vera Therapeutics, Inc. (0001831828) (Subject)

    11/14/24 1:22:39 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care